DR. BRIAN T. BERRY M.D. PHD NPI 1669463378

NPI Details

DR. Brian T. Berry, M.D., PHD is a medical oncology internal medicine in Bradenton, FL with 35 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Brian T. Berry, M.D., PHD NPI is 1669463378. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Graduation Year:1991

The provider's business location address is:

3630 MANATEE AVE W
BRADENTON, FL
ZIP 34205-557
Phone: (941) 792-1881
Fax: (941) 795-3924

The NPI 1669463378 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Folic acid level, serum (HCPCS:82746)
• Magnesium level (HCPCS:83735)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Protein measurement, serum (HCPCS:84165)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• 5% dextrose/normal saline (500 ml = 1 unit) (HCPCS:J7042)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection of drug or substance into vein (HCPCS:96374)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Testosterone (hormone) level, total (HCPCS:84403)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Drawing of blood for a medical problem (HCPCS:99195)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Erythropoietin (protein) level (HCPCS:82668)
• Uric acid level, blood (HCPCS:84550)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Urinalysis, manual test (HCPCS:81002)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Hepatitis b core antibody measurement (HCPCS:86704)
• Thyroxine (thyroid chemical), total (HCPCS:84436)
• Automated urinalysis test (HCPCS:81003)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Transitional care management services for problem of high complexity (HCPCS:99496)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Detection test by immunoassay technique for hepatitis b surface antigen (HCPCS:87340)
• Hepatitis b core antibody (igm) measurement (HCPCS:86705)

The enumeration date for this NPI number is 11/2/2005 and was last updated on 4/29/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.